Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Other Non-Current Liabilities data on file, last reported at $681000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 90.54% year-over-year to $681000.0 in Q1 2026; TTM through Mar 2026 was $681000.0, a 90.54% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, down 42.43% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $681000.0, down from $3.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for AKBA reached as high as $83.1 million in Q1 2022 and fell as low as $681000.0 in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $18.6 million across 5 years, with a median of $5.0 million in 2024.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 3225.64% in 2022 and fell as far as 99.1% in 2022.
• Year by year, Other Non-Current Liabilities stood at $760000.0 in 2022, then changed by 0.0% to $760000.0 in 2023, then surged by 581.05% to $5.2 million in 2024, then slumped by 42.43% to $3.0 million in 2025, then sank by 77.15% to $681000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $681000.0 in Q1 2026, $3.0 million in Q4 2025, and $5.0 million in Q3 2025.